Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Total Current Liabilities (2018 - 2025)

AVITA Medical's Total Current Liabilities history spans 8 years, with the latest figure at $62.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 210.93% year-over-year to $62.7 million; the TTM value through Dec 2025 reached $62.7 million, up 210.93%, while the annual FY2025 figure was $62.7 million, 210.93% up from the prior year.
  • Total Current Liabilities reached $62.7 million in Q4 2025 per RCEL's latest filing, up from $61.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $62.7 million in Q4 2025 to a low of $6.5 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $19.4 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: fell 8.64% in 2021, then surged 354.07% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $9.1 million in 2021, then grew by 16.91% to $10.7 million in 2022, then increased by 23.44% to $13.2 million in 2023, then skyrocketed by 52.72% to $20.2 million in 2024, then surged by 210.93% to $62.7 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Total Current Liabilities are $62.7 million (Q4 2025), $61.8 million (Q3 2025), and $62.6 million (Q2 2025).